Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yasuhiro Aga
Observed names:
Y Aga,
阿賀, 康弘
Institution:
Ube (Japan)
Observed institutions:
Hiroshima University,
Ube (Japan)
OpenAlex ID:
A5001655678
Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate.
1997
·
M Kato
, A Nishida
, et al.
·
PubMed
·
52
UR-3216: A New Generation Oral Platelet GPIIb / IIIa Antagonist
2004
·
Yasuhiro Aga
, Kosuke Baba
, et al.
·
Current Pharmaceutical Design
·
10
UR‐3216: A Manageable Oral GPIIb/IIIa Antagonist
2001
·
Kosuke Baba
, Yasuhiro Aga
, et al.
·
Cardiovascular Drug Reviews
·
10
PDF
Novel Oral Derivative UD-017, a Highly Selective CDK7 Inhibitor, Exhibits Anticancer Activity by Inducing Cell- Cycle Arrest and Apoptosis in Human Colorectal Cancer
2020
·
Yasuhiro Aga
, Takashi Matsushita
, et al.
·
Hiroshima journal of medical sciences
·
3
Abstract 4837: Evaluation of anticancer activities of UD-017, a novel selective and orally available CDK7 inhibitor, in blood cancers
2018
·
Yasuhiro Aga
, Sayaka Ogi
, et al.
·
Cancer Research
·
3
Abstract LB-111: In vitro anti-cancer activity of UD-017, a novel potent & highly selective CDK7 reversible inhibitor
2017
·
Takashi Matsushita
, Kazuhiro Onuma
, et al.
·
Cancer Research
·
3
Preclinical in vitro and in vivo study of UD-017, a novel highly selective and orally available CDK7 inhibitor, in a variety of cancers.
2017
·
Kazuhiro Onuma
, Yasuhiro Aga
, et al.
·
Journal of Clinical Oncology
·
3
Abstract 4835: UD-017, a novel highly selective and orally active CDK7 inhibitor, shows a significant anticancer activity in patient-derived cancers
2018
·
Takashi Matsushita
, Sayaka Ogi
, et al.
·
Cancer Research
·
2
Abstract LB-297: In vivo anti-tumor efficacy of UD-017, a novel highly selective & orally available CDK7 inhibitor, in colorectal cancer cells xenograft models
2017
·
Yasuhiro Aga
, Sayaka Ogi
, et al.
·
Cancer Research
·
2
A novel oral GPIIb/IIIa antagonist, UR-3216. (2) In vivo efficacy and prolongation of bleeding
1999
·
Yasuhiro Aga
, Kosuke Baba
, et al.
·
The Japanese Journal of Pharmacology
·
2
A novel, oral GPIIb/IIIa antagonist, UR-3216. (3)Pharmacokinetics : bioavailability and food-effect
1999
·
Takayuki Nakanishi
, Yasuhiro Aga
, et al.
·
The Japanese Journal of Pharmacology
·
1
Abstract 5707: Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignancies
2024
·
Alison L. Hannah
, Steve Ritland
, et al.
·
Cancer Research
選択的新規経口cdk7阻害剤ud-017は、ヒト大腸癌において細胞周期停止およびアポトーシス誘導を介して抗癌活性を示す
2020
·
阿賀, 康弘
·
Hiroshima University Institutional Repository
PDF
Preclinical in vitro and in vivo evaluation of antitumor activity of UD-017, a novel selective and orally available CDK7 inhibitor, in colorectal cancer.
2017
·
Sayaka Ogi
, Yasuhiro Aga
, et al.
·
Journal of Clinical Oncology
Involvement of integrin alpha 8 beta 1 in development of cardiac failure in patients with diabetes mellitus
2016
·
Yasuhiro Aga
, Norihisa Nishimichi
, et al.
·
The Molecular Biology Society of Japan
Show more works
View as search
Works count:
15
Citation count:
91
H-index:
3
I10-index:
3
Year
Topic
Type